Masayoshi Harigai

14.5k citations

345 papers · 8.1k indexed · 1 hit paper · h-index 46

Rheumatology top 0.1%
Immunology top 1%
Molecular Biology top 5%
Pulmonary and Respiratory Medicine top 1%
Epidemiology top 2%

Co-authors: John C. Reed Hisashi Yamanaka Masahito Hanada Masako Hara Tsutomu Takeuchi Toshiyuki Miyashita Yoshiya Tanaka Nobuyuki Miyasaka
Topics: Rheumatoid Arthritis Research and Therapies (138 papers)Systemic Lupus Erythematosus Research (88 papers)Chronic Lymphocytic Leukemia Research (70 papers)
Cited by: Rheumatology Hematology Genetics
Journals: Journal of Biological ChemistrySHILAP Revista de lepidopterologíaThe Journal of Immunology
Partner nations: Japan United States Austria

In The Last Decade

Masayoshi Harigai

333 papers receiving 8.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification of a p53-dependent negative response element in the bcl-2 gene.

1994 630 citations Masayoshi Harigai et al. profile →

Peers

Countries citing papers authored by Masayoshi Harigai

Since Specialization

Citations

This map shows the geographic impact of Masayoshi Harigai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masayoshi Harigai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masayoshi Harigai more than expected).

Fields of papers citing papers by Masayoshi Harigai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masayoshi Harigai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masayoshi Harigai. The network helps show where Masayoshi Harigai may publish in the future.

Co-authorship network of co-authors of Masayoshi Harigai

This figure shows the co-authorship network connecting the top 25 collaborators of Masayoshi Harigai. A scholar is included among the top collaborators of Masayoshi Harigai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masayoshi Harigai. Masayoshi Harigai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Mortality and risk factors in Japanese patients with rheumatoid arthritis: a 14-year observation of the IORRA cohort 2025 ·Modern Rheumatology ·(unknown),Eiichi Tanaka,Eisuke Inoue,(unknown),(unknown),(unknown),Ayako Nakajima,Hisashi Yamanaka,Masayoshi Harigai	1
2	2024 Update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis: Secondary publication 2025 ·Modern Rheumatology ·Masayoshi Harigai,Yuko Kaneko,Eiichi Tanaka,Shintaro Hirata,Hideto Kameda,Kayoko Kaneko,Mitsumasa Kishimoto,Masataka Kohno,Masayo Kojima,Toshihisa Kojima,Akio Morinobu,Ayako Nakajima,Takahiko Sugihara,(unknown),Nobuyuki Yajima,(unknown),Yutaka Kawahito	4
3	Nationwide epidemiological survey of polyarteritis nodosa in Japan in 2020 2024 ·Modern Rheumatology ·(unknown),Toshihiro Nanki,Keigo Saeki,Hideki Ishikawa,Yoshikazu Nakamura,(unknown),Shuichi Ito,Masanari Kodera,(unknown),Shinya Kaname,Masayoshi Harigai	2
4	Higher risk of poor functional outcome and unfavourable clinical events for late-onset rheumatoid arthritis: results from the IORRA cohort 2024 ·Lara D. Veeken ·(unknown),Eiichi Tanaka,Eisuke Inoue,(unknown),(unknown),(unknown),(unknown),Rei Yamaguchi,(unknown),Hisashi Yamanaka,Masayoshi Harigai	2
5	AB0219 LONG-TERM OUTCOMES OF METHOTREXATE IN ELDERLY-ONSET RA IMPLEMENTING THE TREAT-TO-TARGET STRATEGY 2023 ·Annals of the Rheumatic Diseases ·(unknown),Takahiko Sugihara,Tatsuro Ishizaki,(unknown),Tadashi Hosoya,Mari Kamiya,(unknown),(unknown),Fumio Hirano,N. Miyasaka,Masayo Kojima,Shinsuke Yasuda,Masayoshi Harigai	1
6	AB0286 RETENTION RATE OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH DECREASED KIDNEY FUNCTION: RESULTS FROM THE IORRA COHORT 2023 ·Annals of the Rheumatic Diseases ·Tomoyuki Higuchi,Eiichi Tanaka,Eisuke Inoue,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Rei Yamaguchi,Katsunori Ikari,(unknown),Masayoshi Harigai	1
7	Unincreased mortality of patients with early rheumatoid arthritis compared to the general population in the past 17 years: Analyses from the IORRA cohort 2023 ·Modern Rheumatology ·(unknown),Eiichi Tanaka,Eisuke Inoue,(unknown),(unknown),(unknown),(unknown),(unknown),Rei Yamaguchi,Naoki Sugimoto,Katsunori Ikari,Ayako Nakajima,Hisashi Yamanaka,Masayoshi Harigai	1
8	Factors associated with sarcopenia in Japanese patients with rheumatoid arthritis: results from the IORRA cohort study 2023 ·Clinical Rheumatology ·(unknown),Takefumi Furuya,Eisuke Inoue,Eiichi Tanaka,Katsunori Ikari,Hisashi Yamanaka,Masayoshi Harigai	9
9	Impact of interstitial lung disease on clinical remission and unfavourable events of rheumatoid arthritis: results from the IORRA cohort 2023 ·Lara D. Veeken ·(unknown),Eiichi Tanaka,Eisuke Inoue,Suguru Honda,(unknown),(unknown),(unknown),(unknown),Rei Yamaguchi,Katsunori Ikari,Masayoshi Harigai	3
10	Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Interim analysis of post-marketing surveillance 2023 ·Modern Rheumatology ·Masataka Kuwana,Naonobu Sugiyama,Shigeki Momohara,Tatsuya Atsumi,Syuji Takei,Naoto Tamura,Masayoshi Harigai,Takao Fujii,Hiroaki Matsuno,Tsutomu Takeuchi,Kazuhiko Yamamoto,Yoshinari Takasaki,(unknown),Yutaka Endo,Tomohiro Hirose,Yosuke Morishima,(unknown),Tsuneyo Mimori,Michiaki Takagi	6
11	Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data 2022 ·PLoS ONE ·Eiichi Tanaka,Eisuke Inoue,Ayako Shoji,(unknown),(unknown),Devender Dhanda,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Rei Yamaguchi,Katsunori Ikari,Hisashi Yamanaka,Masayoshi Harigai	3
12	Association between patient-reported outcomes and impairments in work and activity in patients with rheumatoid arthritis in clinical remission: A retrospective analysis using the IORRA database 2022 ·Modern Rheumatology ·Ryoko Sakai,Eiichi Tanaka,Eisuke Inoue,Minako Sato,Masaru Tanaka,Katsunori Ikari,Hisashi Yamanaka,Masayoshi Harigai	4
13	Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis—secondary publication 2022 ·Modern Rheumatology ·Yutaka Kawahito,Akio Morinobu,Yuko Kaneko,Masataka Kohno,Shintaro Hirata,Mitsumasa Kishimoto,Yohei Seto,Takahiko Sugihara,Eiichi Tanaka,Hiromu Ito,Toshihisa Kojima,Isao Matsushita,Keiichiro Nishida,Masaaki Mori,Atsuko Murashima,Hisashi Yamanaka,Takeo Nakayama,Masayo Kojima,Masayoshi Harigai	57
14	Real-world effectiveness and safety of tofacitinib and abatacept in patients with rheumatoid arthritis 2022 ·Rheumatology Advances in Practice ·Wataru Hirose,Masayoshi Harigai,Koichi Amano,Toshihiko Hidaka,Kenji Itoh,(unknown),Masahiro Nakashima,Hayato Nagasawa,Yukiko Komano,Toshihiro Nanki	4
15	Patients’ perspectives of rheumatoid arthritis treatment: a questionnaire survey for the 2020 update of the Japan college of rheumatology clinical practice guidelines 2021 ·Modern Rheumatology ·Masayo Kojima,(unknown),Shintaro Hirata,Hiromu Ito,Yuko Kaneko,Mitsumasa Kishimoto,Masataka Kohno,Toshihisa Kojima,Isao Matsushita,Masaaki Mori,Akio Morinobu,Atsuko Murashima,Keiichiro Nishida,Yohei Seto,Yasumori Sobue,Takahiko Sugihara,Eiichi Tanaka,Takeo Nakayama,Yutaka Kawahito,Masayoshi Harigai	5
16	Systematic review for the treatment of older rheumatoid arthritis patients informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis 2021 ·Modern Rheumatology ·Takahiko Sugihara,Yutaka Kawahito,Akio Morinobu,Yuko Kaneko,Yohei Seto,Toshihisa Kojima,Hiromu Ito,Masataka Kohno,Takeo Nakayama,Yasumori Sobue,Keiichiro Nishida,Isao Matsushita,Atsuko Murashima,Masaaki Mori,Eiichi Tanaka,Shintaro Hirata,Mitsumasa Kishimoto,Hisashi Yamanaka,Masayo Kojima,Masayoshi Harigai	11
17	Patient satisfaction with total joint replacement surgery for rheumatoid arthritis: a questionnaire survey for the 2020 update of the Japan college of rheumatology clinical practice guidelines 2021 ·Modern Rheumatology ·Yasumori Sobue,Masayo Kojima,Toshihisa Kojima,Hiromu Ito,Keiichiro Nishida,Isao Matsushita,Shintaro Hirata,Yuko Kaneko,Mitsumasa Kishimoto,Masataka Kohno,Atsuko Murashima,Akio Morinobu,Masaaki Mori,Takeo Nakayama,Takahiko Sugihara,Yohei Seto,Eiichi Tanaka,(unknown),Yutaka Kawahito,Masayoshi Harigai	2
18	Association Between Reappearance of Myeloperoxidase–Antineutrophil Cytoplasmic Antibody and Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis 2018 ·Arthritis & Rheumatology ·Haruki Watanabe,Ken‐ei Sada,Yoshinori Matsumoto,Masayoshi Harigai,Koichi Amano,Hiroaki Dobashi,Shouichi Fujimoto,Joichi Usui,Kunihiro Yamagata,Tatsuya Atsumi,Shogo Banno,Takahiko Sugihara,Yoshihiro Arimura,Seiichi Matsuo,Hirofumi Makino	28
19	Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T) 2018 ·Modern Rheumatology ·Yoshiya Tanaka,Tsutomu Takeuchi,Masayoshi Harigai,Hisashi Yamanaka,(unknown),(unknown),(unknown),Benjamin Hsu	3
20	A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis 2012 ·Modern Rheumatology ·S Kobayashi,Masayoshi Harigai,Neelufar Mozaffarian,Aileen L. Pangan,Shringi Sharma,L Brown,Nobuyuki Miyasaka	12

About Masayoshi Harigai

Masayoshi Harigai is a scholar working on Rheumatology, Genetics and Hematology, having authored 345 papers that have together received 8.1k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (138 papers), Systemic Lupus Erythematosus Research (88 papers) and Chronic Lymphocytic Leukemia Research (70 papers). The work is most often cited by research in Rheumatology (3.7k citations), Hematology (1.2k citations) and Genetics (1.1k citations). Masayoshi Harigai has collaborated with scholars based in Japan, United States and Austria. Frequent co-authors include John C. Reed, Hisashi Yamanaka, Masahito Hanada, Masako Hara, Tsutomu Takeuchi, Toshiyuki Miyashita, Yoshiya Tanaka, Nobuyuki Miyasaka, Yasushi Kawaguchi and Naoki Ishiguro. Their work appears in journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact